Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: Extension of the 2PRECISE study - 11/01/21
Doi : 10.1016/j.jaad.2020.06.038
Ulrich Mrowietz, MD a, ⁎ 
, Hervé Bachelez, MD b, c, Arthur David Burden, MD, FRCP d, Michael Rissler, PhD e, Christian Sieder, PhD f, Roberto Orsenigo, MD g, Piotr Jagiello, MD, PhD e
, Hervé Bachelez, MD b, c, Arthur David Burden, MD, FRCP d, Michael Rissler, PhD e, Christian Sieder, PhD f, Roberto Orsenigo, MD g, Piotr Jagiello, MD, PhD e a Psoriasis Center at the Department of Dermatology, University Medical Center, Schleswig-Holstein, Campus Kiel, Germany
b Service de Dermatologie, Hôpital Saint-Louis, Sorbonne Paris Cité Université Paris Diderot, Paris, France
c Inserm UMR1163, Institut Imagine, Paris, France
d Institute of Infection Inflammation and Immunity, University of Glasgow, United Kingdom
e Novartis Pharma, Basel, Switzerland
f Novartis Pharma GmbH, Nuernberg, Germany
g Novartis Farma SpA, Origgio, Italy
∗Correspondence to: Ulrich Mrowietz, MD, Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus C, 24105 Kiel, GermanyKlinik für DermatologieVenerologie und AllergologieUniversitätsklinikum Schleswig-Holstein, Campus KielArnold-Heller-Str. 3, Haus CKiel24105Germany
| Funding sources: The 2PRECISE study was funded by Novartis Pharma AG, Basel, Switzerland. |
|
| Disclosure: Dr Mrowietz reports grants and personal fees from Novartis and personal fees from Almirall, AbbVie, Boehringer Ingelheim, Celgene, Janssen, Lilly, and UCB during the conduct of the study. Dr Bachelez reports grants and personal fees from Novartis and personal fees from Almirall, AbbVie, Boehringer Ingelheim, Celgene, Janssen, Lilly, and UCB during the conduct of the study. Dr Burden reports grants and personal fees from Novartis and personal fees from Almirall, AbbVie, Boehringer Ingelheim, Celgene, Janssen, Lilly, and UCB during the conduct of the study. Drs Rissler, Sieder, Orsenigo, and Jagiello are employees of Novartis. |
|
| IRB approval status: Approved by participating centers. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 84 - N° 2
P. 552-554 - février 2021 Retour au numéro
Article précédent
- Large nuclear size correlated with better overall survival, Merkel cell polyomavirus positivity, and terminal deoxynucleotidyl transferase expression in Merkel cell carcinoma
- Jakob M.T. Moran, Przemyslaw Biecek, Piotr Donizy, Cheng-Lin Wu, Janusz Kopczynski, Malgorzata Pieniazek, Janusz Ry?, Mai P. Hoang
- A pilot study of the impact of facial skin protectants on qualitative fit testing of N95 masks
- Ai-Tram N. Bui, Zizi Yu, Karen Lee, Sara J. Li, William G. Tsiaras, Sherry H. Yu, Nicole R. LeBoeuf, Arash Mostaghimi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?